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Abstract
Background: The coronavirus disease (COVID-19) has been identified as the cause of an outbreak of respiratory
illness in Wuhan, Hubei Province, China beginning in December 2019. As of 31 January 2020, this epidemic had
spread to 19 countries with 11 791 confirmed cases, including 213 deaths. The World Health Organization has
declared it a Public Health Emergency of International Concern.
Methods: A scoping review was conducted following the methodological framework suggested by Arksey and
O’Malley. In this scoping review, 65 research articles published before 31 January 2020 were analyzed and discussed
to better understand the epidemiology, causes, clinical diagnosis, prevention and control of this virus. The research
domains, dates of publication, journal language, authors’ affiliations, and methodological characteristics were
included in the analysis. All the findings and statements in this review regarding the outbreak are based on
published information as listed in the references.
Results: Most of the publications were written using the English language (89.2%). The largest proportion of
published articles were related to causes (38.5%) and a majority (67.7%) were published by Chinese scholars.
Research articles initially focused on causes, but over time there was an increase of the articles related to
prevention and control. Studies thus far have shown that the virus’ origination is in connection to a seafood market
in Wuhan, but specific animal associations have not been confirmed. Reported symptoms include fever, cough,
fatigue, pneumonia, headache, diarrhea, hemoptysis, and dyspnea. Preventive measures such as masks, hand
hygiene practices, avoidance of public contact, case detection, contact tracing, and quarantines have been
discussed as ways to reduce transmission. To date, no specific antiviral treatment has proven effective; hence,
infected people primarily rely on symptomatic treatment and supportive care.
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Conclusions: There has been a rapid surge in research in response to the outbreak of COVID-19. During this early
period, published research primarily explored the epidemiology, causes, clinical manifestation and diagnosis, as well
as prevention and control of the novel coronavirus. Although these studies are relevant to control the current
public emergency, more high-quality research is needed to provide valid and reliable ways to manage this kind of
public health emergency in both the short- and long-term.
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Background
The coronavirus belongs to a family of viruses that may
cause various symptoms such as pneumonia, fever,
breathing difficulty, and lung infection [1]. These viruses
are common in animals worldwide, but very few cases
have been known to affect humans. The World Health
Organization (WHO) used the term 2019 novel corona-
virus to refer to a coronavirus that affected the lower re-
spiratory tract of patients with pneumonia in Wuhan,
China on 29 December 2019 [2–4]. The WHO an-
nounced that the official name of the 2019 novel corona-
virus is coronavirus disease (COVID-19) [4]. And the
current reference name for the virus is severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2). It was
reported that a cluster of patients with pneumonia of
unknown cause was linked to a local Huanan South
China Seafood Market in Wuhan, Hubei Province, China
in December 2019 [5].
In response to the outbreak, the Chinese Center for
Disease Control and Prevention (China CDC) dispatched
a rapid response team to accompany health authorities
of Hubei province and Wuhan city to conduct epidemio-
logical and etiological investigations. The WHO con-
firmed that the outbreak of the coronavirus epidemic
was associated with the Huanan South China Seafood
Marketplace, but no specific animal association was
identified [6]. Scientists immediately started to research
the source of the new coronavirus, and the first genome
of COVID-19 was published by the research team led by
Prof. Yong-Zhen Zhang, on 10 January 2020 [7]. Within
1 month, this virus spread quickly throughout China
during the Chinese New Year – a period when there is a
high level of human mobility among Chinese people. Al-
though it is still too early to predict susceptible popula-
tions, early patterns have shown a trend similar to
Severe Acute Respiratory Syndrome (SARS) and Middle
East respiratory syndrome (MERS) coronaviruses. Sus-
ceptibility seems to be associated with age, biological
sex, and other health conditions [8]. COVID-19 has now
been declared as a Public Health Emergency of Inter-
national Concern by the WHO [9].
Given the spread of the new coronavirus and its impacts
on human health, the research community has responded
rapidly to the new virus and many preliminary research
articles have already been published about this epidemic
(Additional file 1). We conducted a scoping review to
summarize and critically analyze all the published scien-
tific articles regarding the new coronavirus in January
2020. This review aims to provide the evidence of early
findings on the epidemiology, causes, clinical diagnosis, as
well as prevention and control of COVID-19 in relation to
time, location, and source of publication. This review can
provide meaningful information for future research related
to this topic and may support government decision-
making on strategies to handle this public health emer-
gency at the community, national, and international levels.
Methods
Study design
A scoping review was conducted following the methodo-
logical framework suggested by Arksey and O’Malley
[10]. The following five steps were followed to conduct
this scoping review: a) identifying a clear research ob-
jective and search strategies, b) identifying relevant re-
search articles, c) selection of research articles, d)
extraction and charting of data, and e) summarizing, dis-
cussing, analyzing, and reporting the results.
Literature search strategies
Literature for this review was identified by searching the
following online databases: bioRxiv, medRxiv, ChemRxiv,
Google scholar, PubMed, as well as CNKI and WanFang
Data (the two primary databases for biomedical research
in mainland China). These online databases contain ar-
chives of most English and Chinese biomedical journals.
In addition, some white papers published online by the
National Health Commission of the People’s Republic of
China, Chinese Center for Disease Prevention and Con-
trol, and the WHO were included in the analysis. We
searched scientific publications from 1 January to 31
January 2020. The search terms were ‘nCoV’, ‘2019 novel
coronavirus’, ‘2019-nCoV’, ‘novel coronavirus’, ‘Pneumo-
nia’, ‘新型冠状病毒’ (Chinese), ‘新型肺炎’ (Chinese),
and ‘新冠病毒’ (Chinese). We included all the relevant
scientific publications written in English or Chinese in
the review. Non-scientific commentary, reports, and
news articles were excluded from the analysis.
Adhikari et al. Infectious Diseases of Poverty            (2020) 9:29 Page 2 of 12
Identification and selection of relevant studies
Two researchers (YW and SPA) independently searched
through the literature. The two sets of literature were then
compared. Disagreements on the inclusion or exclusion of
literature were resolved through discussion or, if neces-
sary, by including a third researcher (HZ) to make the
final decision. Duplicate articles were eliminated. Eventu-
ally, 65 unique academic publications were included in
this analysis (Additional file 1). Figure 1 presents a Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flow diagram showing the process of
searching and selecting the research articles [11].
Data extraction from the included studies
After the articles were selected, data were extracted and
recorded in an excel spreadsheet. The extracted data were
date of publication, language of publication, title of article,
name of journal, author’s country and affiliation, study de-
sign, targets of study, sample size, study setting, data col-
lection instrument, research domain, and key findings.
Summarizing the findings
Based on the main research objectives, articles were classi-
fied into one of the following four research domains: epi-
demiology, causes, clinical manifestation and diagnosis, or
prevention and control. ‘Epidemiology’ includes studies on
the epidemic distribution (when, where, who); ‘causes’ in-
cludes studies on virology, pathogenesis, and transmission
patterns; ‘clinical manifestation and diagnosis’ includes
studies on the clinical features (signs and symptoms) and
diagnosis; and ‘prevention and control’ includes studies on
prevention, control, and treatment measures.
Authors’ affiliations were used to categorize the type of
research collaboration. A publication was considered as
deriving from ‘inside China’ when all affiliations of the au-
thors were from China; a publication was considered as
deriving from ‘outside China’ when all affiliations were
outside China; a publication was considered as deriving
from ‘international collaboration’ when at least one affili-
ation was from China and at least one was from outside
China. The research domains, publishing dates, journal
language, authors’ affiliations, as well as methodological
characteristics were analyzed respectively. All findings and
statements regarding the outbreak in this review are based
on published information as listed in the references.
Results and discussion
Characteristics of published studies
Among the 65 research articles included in the analysis,
more than 31 are on preprint servers, and 34 are
Fig. 1 PRISMA flow diagram for the scoping review process
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published in peer-reviewed journals, including The Lan-
cet and The New England Journal of Medicine. Most of
the publications (n = 58, 89.2%) are in English and few
(n = 7, 10.8%) are in Chinese. Around 75.9% of English
language publications focus on epidemiology and causes,
while 85.7% of Chinese papers focus on prevention and
control (Table 1).
As shown in Fig. 2, academic publications are distrib-
uted across the following research domains: epidemi-
ology, causes, clinical manifestation and diagnosis, and
prevention and control. The largest portion of the pa-
pers (n = 25, 38.5%) are related to causes, followed by pa-
pers on epidemiology (n = 19, 29.2%), while 18.5%
examined prevention and control and 13.8% reported
clinical manifestations and diagnosis. Initially, there were
more research articles focused on causes of the out-
break, yet studies on prevention and control gradually
increased over time (Fig. 3). The majority of the articles
(n = 44, 67.7%) were published by Chinese scholars
whereas 29.2% (n = 19) articles were from scholars out-
side of China. A small number (n = 2, 3.1%) were based
on international collaborative research by scholars from
different countries (Table 2).
We also analyzed the methodological characteristics of
the publications in the final sample. The majority of the
articles are based on mathematical modeling (44.6%) and
cross-sectional study designs (18.5%). Around half of the
studies include targeted populations (patients, general
populations, and healthcare workers) (49.2%) in their
analysis, followed by studies that attempt to identify the
species of the virus (virus structure, gene sequence)
(36.9%). Among the 32 articles with population as the
target of study, 34.4% had a sample size of less than 10,
31.3% were conducted in a hospital setting, and 50%
used secondary data. Quality control activities for data




On 29 December 2019, the first four cases of an acute
respiratory syndrome of unknown etiology were re-
ported in Wuhan City, Hubei Province, China among
people linked to a local seafood market (“wet market”)
[2]. Research is underway to understand more about
transmissibility, severity, and other features associated
with COVID-19 [3]. It appears that most of the early
cases had some sort of contact history with the original
seafood market [2, 12–14]. Soon, a secondary source of
infection was found to be human-to-human transmis-
sion via close contact. There was an increase of infected
people with no history of exposure to wildlife or visiting
Wuhan, and multiple cases of infection were detected
among medical professionals [2, 14–17]. It became clear
that the COVID-19 infection occurs through exposure
to the virus, and both the immunosuppressed and nor-
mal population appear susceptible. Some studies have
reported an age distribution of adult patients between 25
and 89 years old. Most adult patients were between 35
and 55 years old [14], and there were fewer identified
cases among children and infants [14, 18]. A study on
early transmission dynamics of the virus reported the
median age of patients to be 59 years, ranging from 15
to 89 years, with the majority (59%) being male [2]. It
was suggested that the population most at risk may be
people with poor immune function such as older people
and those with renal and hepatic dysfunction [2].
The COVID-19 has been found to have higher levels
of transmissibility and pandemic risk than the SARS-
CoV, as the effective reproductive number (R) of
COVID-19 (2.9) is estimated to be higher than the re-
ported effective reproduction number (R) of SARS (1.77)
at this early stage [15]. Different studies of COVID-19
have estimated the basic reproduction (R0) range to be
from 2.6 to 4.71 (Table 4). The average incubation dur-
ation of COVID-19 was estimated to be 4.8 ± 2.6, ran-
ging from 2 to 11 days [15] and 5.2 days (95% confidence
interval, 4.1 to 7) [2]. The latest guidelines from Chinese
health authorities stated an average incubation duration
of 7 days, ranging from 2 to 14 days [23]. Table 4 sum-
marizes the findings on important indicators from these
epidemiological studies.
In China, 11 791 cases were confirmed and 17 988
cases were suspected in 34 provinces as of 24:00, 31
January 2020 (Fig. 4) [32]. Studies indicated that the
spread of COVID-19 was relatively quick and reported
that it had spread to several other countries after its out-
break in China. On 31 January 2020, there were 213
Table 1 Breakdown of research domains by language in January 2020
Research domains English literature Chinese literature Total
n % n % n %
Epidemiology 19 32.8 0 0.0 19 29.2
Causes 25 43.1 0 0.0 25 38.5
Clinical manifestation and diagnosis 8 13.8 1 14.3 9 13.8
Prevention and control 6 10.3 6 85.7 12 18.5
Total 58 89.2 7 10.8 65 100
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deaths reported globally [33]. Confirmed cases were re-
ported in the following 19 countries outside of China:
Australia (9), Canada (3), Cambodia (1), France (6),
Finland (1), Germany (5), India (1), Italy (2), Japan (14),
Nepal (1), Malaysia (8), the Philippines (1), the Republic
of Korea (11), Singapore (13), Sri Lanka (1), Thailand
(14), the United States of America (6), United Arab
Emirates (4) and Vietnam (5) (Fig. 5) [33].
Causes
Virology and pathogenesis Coronaviruses are envel-
oped single-stranded RNA viruses that are zoonotic in
nature and cause symptoms ranging from those similar
to the common cold to more severe respiratory, enteric,
hepatic, and neurological symptoms [5, 34]. Other than
SARS-CoV-2, there are six known coronaviruses in
humans: HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-
NL63, HCoV-HKU1, and MERS-CoV [2, 23, 35, 36].
Coronavirus has caused two large-scale pandemics in
the last two decades: SARS [37] and MERS [12, 38].
To detect the infection source of COVID-19, China CDC
researchers collected 585 environmental samples from the
Huanan Seafood Market in Wuhan, Hubei Province, China
on 1 January and 12 January 2020. They detected 33 samples
containing SARS-CoV-2 and indicated that it originated
from wild animals sold in the market [39]. Then, researchers
used the lung fluid, blood, and throat swab samples of 15 pa-
tients to conduct laboratory tests. These laboratory tests
found that the virus-specific nucleic acid sequences in the
sample are different from those of known human corona-
virus species. Laboratory results also indicated that SARS-
CoV-2 is similar to some of the beta (β) coronaviruses gen-
era identified in bats [12, 18, 40], which is situated in a group
of SARS/SARS-like CoV [12].
To conduct next-generation sequencing from bron-
choalveolar lavage fluid and cultured isolates, researchers
enrolled nine inpatients in Wuhan with viral pneumonia
and negative in common respiratory pathogens. The re-
sults of this next-generation sequencing indicated that
SARS-CoV-2 was more distant from SARS-CoV (with
Fig. 2 Research domains of published research articles
Fig. 3 Publication dates of research articles
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Table 2 Breakdown of research domains by collaboration type in January 2020
Research domains Inside China Outside China International collaboration Total
n % n % n % n %
Epidemiology 8 18.2 9 47.4 2 100 19 29.2
Causes 17 38.6 8 42.1 0 0.0 25 38.5
Clinical manifestation and diagnosis 8 18.2 1 5.3 0 0.0 9 13.8
Prevention and control 11 25.0 1 5.3 0 0.0 12 18.5
Total 44 67.7 19 29.2 2 3.1 65 100
Table 3 Methodological characteristics of COVID-19 research articles in January 2020
Characteristics Categories n %
Study design
(n = 65)
Cross-sectional studies 12 18.5
Mathematical modeling 29 44.6
Molecular studies 10 15.4
Diagnostic studies 2 3.1
Review 3 4.6





General population 6 9.2
Healthcare workers 4 6.2
Species (virus structure, gene sequence) 24 36.9
Other 9 13.9
Study related to population (n = 32)
Sample size 1–10 11 34.4
11–50 5 15.6
51–100 3 9.4
> 100 3 9.4
Not specified 10 31.3
Study setting Laboratory 2 6.3
Hospital 10 31.3
Community 0 0.0
Hospital and community 0 0.0
Not specified 20 62.5
Questionnaire 7 10.8
Data-collection instrumenta Biological specimen collection 1 3.1
Physical examinations 0 0.0
Environmental sample 0 0.0
Hospital, medical, or exposure records 14 43.7
Secondary data 16 50.0
Quality-control activities for data collection Indicated in the article 14 56.3
Not specified 18 43.8
a Percentages in this section do not add up to 100% because multiple answers were possible
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about 79% sequence identity) and MERS-CoV (with
about 50% sequence identity) than from two bat-derived
SARS-like coronaviruses – bat-SL-CoVZC45 (with
87.9% sequence identity) and bat-SL-CoVZXC21 (with
87.2% sequence identity) [41]. Studies also reported that
COVID-19 S-protein supported strong interaction with
human ACE2 molecules despite the dissimilarity of its
sequence with that of SARS-CoV [12, 42].
Transmission pattern Many domestic and wild animals,
including camels, cattle, cats, and bats, may serve as hosts
for coronaviruses [23]. It is considered that, generally,
animal coronaviruses do not spread among humans [3].
However, there are exceptions, such as SARS and MERS,
which are mainly spread though close contact with in-
fected people via respiratory droplets from cough or
sneezing. With regard to COVID-19, early patients were
reported to have some link to the Huanan Seafood Market
in Wuhan, China, suggesting that these early infections
were due to animal-to-person transmission. However,
later cases were reported among medical staff and others
with no history of exposure to that market or visiting Wu-
han, which was taken as an indication of human-to-
human transmission [2, 4, 15–17].
Table 4 Main epidemiological indicators of COVID-19 research articles in January 2020
Indicators Description
Age of patients • Cases range between 25 and 89 years, with most patients aged between 35 and 55 years and fewer cases among children
and infants [14]
• Median age of patients is 59 years, ranging from 51 to 89 [2]
• Average age of patients was 55.5 years; age distribution: ≤ 39: 10%; 40–49: 22%, 50–59: 30%; 60–69: 22%, ≥ 70: 15% [19]
• Cases range from 2 to 72 years [20]
Sex of patients • More cases were males [20]
• 59% males [2]
• 68% males [19]
Age of the deaths • Median age of death was 75 (with a range between 48 and 89 years) [21]
Exposure history • Huanan Seafood Market in Wuhan [19, 22]
• Wuhan residents or people who visited Wuhan [20]
Incubation time • 4.8 ± 2.6 days (2–11 days) [15]
• 5.2 days (4.1–7 days) [2]
• Average of 7 days (2–14 days) [23]
• Average of 10 days [22]
• 5–6 days [24]
• Average of 6.4 days (5.6–7.7 days) [20]
Basic Reproduction
(R0)
• 2.6 (uncertainty range: 1.5–3.5) [25]
• 3.8 (95% CI: 3.6–4.0) [26]
• 2.2 (1.4–3.8) [27]
• 4.71 (4.50–4.92) [24]
• 2.68 (95% CI: 2.47–2.86) [28]
Susceptible
populations
• Elderly people [21]
• People with poor immune function [2]
• People with chronic co-morbidities [2, 15, 19, 21]
• People with long-term use of immunosuppressive agents [19]
• Surgery history before admission [21]
Mortality rate • 3% (between 29 December 2019 to 23 January, 2020) [15]
• 2.3% (as of 28 January 2020) [29]
• 2.8% (as of 25 January, 2020) [21]
• 2.9% (as of 25 January, 2020) [30]
• 11% (as of 25 January, 2020) [19]
• 3.1% (as of 24 January 2020) [31]
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The latest guidelines from Chinese health author-
ities [23, 43] described three main transmission routes
for the COVID-19: 1) droplets transmission, 2) con-
tact transmission, and 3) aerosol transmission. Drop-
lets transmission was reported to occur when
respiratory droplets (as produced when an infected
person coughs or sneezes) are ingested or inhaled by
individuals nearby in close proximity; contact trans-
mission may occur when a subject touches a surface
or object contaminated with the virus and subse-
quently touch their mouth, nose, or eyes; and aerosol
transmission may occur when respiratory droplets
mix into the air, forming aerosols and may cause in-
fection when inhaled high dose of aerosols into the
lungs in a relatively closed environment [23, 43]. In
addition to these three routes, one study also indi-
cated the digestive system as a potential transmission
route for COVID-19 infection. Since patients had ab-
dominal discomfort and diarrhea symptoms, re-
searchers analyzed four datasets with single-cell
transcriptomes of digestive systems and found that
ACE2 was highly expressed in absorptive enterocytes
from ileum and colon [44].
Clinical manifestation and diagnosis
The complete clinical manifestation is not clear yet, as
the reported symptoms range from mild to severe, with
some cases even resulting in death [3]. The most com-
monly reported symptoms are fever, cough, myalgia or
fatigue, pneumonia, and complicated dyspnea, whereas
less common reported symptoms include headache,
diarrhea, hemoptysis, runny nose, and phlegm-
producing cough [3, 16]. Patients with mild symptoms
were reported to recover after 1 week while severe cases
were reported to experience progressive respiratory fail-
ure due to alveolar damage from the virus, which may
lead to death [13]. Cases resulting in death were primar-
ily middle-aged and elderly patients with pre-existing dis-
eases (tumor surgery, cirrhosis, hypertension, coronary
heart disease, diabetes, and Parkinson’s disease) [13]. Case
definition guidelines mention the following symptoms:
fever, decrease in lymphocytes and white blood cells, new
Fig. 4 Distribution of COVID-19 cases in China
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pulmonary infiltrates on chest radiography, and no im-
provement in symptoms after 3 days of antibiotics treat-
ment [2].
For patients with suspected infection, the following
procedures have been suggested for diagnosis: perform-
ing real-time fluorescence (RT-PCR) to detect the posi-
tive nucleic acid of SARS-CoV-2 in sputum, throat
swabs, and secretions of the lower respiratory tract
samples [13, 14, 43].
Prevention and control
Prevention and control strategies and methods are reported
at three levels: national level, case-related population level,
and general population level. At the national level, the Na-
tional Health Commission of the People’s Republic of China
issued the “No.1 announcement” on 20 January 2020, which
officially included the COVID-19 into the management of
class B legal infectious diseases, and allowed for class A infec-
tious disease preventive and control measures to be imple-
mented [45]. Under this policy, medical institutes can adopt
isolation treatment and observation protocols to prevent and
control the spread of the COVID-19. On 22 January 2020,
the National Health Commission published national guide-
lines for the prevention and control of COVID-19 for med-
ical institutes to prevent nosocomial infection [46]. On 28
January 2020, the National Health Commission issued proto-
cols for rapid prevention and control measures in order to
effectively contain the spread of the epidemic through a “big
isolation and big disinfection” policy during the Chinese
Spring Festival [47]. National-level strategies have also been
issued with targeted measures for rural areas (issued on 28
January 2020) and the elderly population (issued on 31 Janu-
ary 2020) [48, 49]. Several public health measures that may
prevent or slow down the transmission of the COVID-19
were introduced; these include case isolation, identification
and follow-up of contacts, environmental disinfection, and
use of personal protective equipment [50].
To date, no specific antiviral treatment has been
confirmed to be effective against COVID-19. Regarding
patients infected with COVID-19, it has been recom-
mended to apply appropriate symptomatic treatment
and supportive care [3, 16]. There are six clinical trials
registered in both the International Clinical Trials Regis-
try platform and the Chinese Clinical Trial Registry to
evaluate the efficacy or safety of targeted medicine in the
treatment or prognosis of COVID-19 (Additional file 2)
[51, 52]. Regarding infected patients with COVID-19, it
has been recommended to apply appropriate symptom-
atic treatment and supportive care [3, 16]. Studies have
also explored the prevention of nosocomial infection
Fig. 5 Global distribution of COVID-19 cases
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and psychological health issues associated with COVID-
19. A series of measures have been suggested to reduce
nosocomial infection, including knowledge training for
prevention and control, isolation, disinfection, classified
protections at different degrees in infection areas, and
protection of confirmed cases [18, 50, 53]. Concerning
psychological health, some suggested psychological
intervention for confirmed cases, suspected cases, and
medical staff [18, 54].
For the general population, at this moment there is
no vaccine preventing COVID-19. The best preven-
tion is to avoid being exposed to the virus [55]. Air-
borne precautions and other protective measures have
been discussed and proposed for prevention. Infection
preventive and control (IPC) measures that may re-
duce the risk of exposure include the following: use
of face masks; covering coughs and sneezes with tis-
sues that are then safely disposed of (or, if no tissues
are available, use a flexed elbow to cover the cough
or sneeze); regular hand washing with soap or disin-
fection with hand sanitizer containing at least 60% al-
cohol (if soap and water are not available); avoidance
of contact with infected people and maintaining an
appropriate distance as much as possible; and refrain-
ing from touching eyes, nose, and mouth with un-
washed hands [3].
The WHO also issued detailed guidelines on the use
of face masks in the community, during care at home,
and in the health care settings of COVID-19 [56]. In this
document, health care workers are recommended to use
particulate respirators such as those certified N95 or
FFP2 when performing aerosol-generating procedures
and to use medical masks while providing any care to
suspected or confirmed cases. According to this guide-
line, individuals with respiratory symptoms are advised
to use medical masks both in health care and home care
settings properly following the infection prevention
guidelines. According to this guideline, an individual
without respiratory symptoms is not required to wear a
medical mask when in public. Proper use and disposal of
masks is important to avoid any increase in risk of trans-
mission [56].
In addition to articles published in research journals,
the China CDC published a guideline to raise awareness
of the prevention and control of COVID-19 among the
general population. The key messages of the guideline
include causes, how to choose and wear face masks,
proper hand washing habits, preventive measures at dif-
ferent locations (e.g., at home, on public transportation,
and in public space), disinfection methods, and medical
observation at home [57]. In addition to scientific know-
ledge on ways to handle the COVID-19 outbreak, the
guideline also suggests ways to eliminate panic among
the general population [57].
Strengths and limitations of the study
The review applied a systematic and rigorous search
strategy to retrieve relevant articles according to the re-
search objectives. This research summarizes scientific
foundations, identifies literature gaps, and suggests some
evidence for future research directions on COVID-19
which will provide information for research community,
policymakers, and health professionals to adjust and/or
come up with new research, policies, and practices. Our
study only focuses on the articles published either in
English or in Chinese during the early outbreak period.
Although, it cannot reflect the entire body of research
on COVID-19 worldwide, it will provide some evidences
for future study and control.
Conclusions
This study shows a holistic picture of the current re-
search in response to the outbreak of COVID-19. During
this early period, many studies have been published ex-
ploring the epidemiology, causes, clinical manifestation
and diagnosis, and prevention and control of the novel
coronavirus. Thus far, most studies have focused on the
epidemiology and potential causes. However, studies ex-
ploring prevention and control measures have begun to
gradually increase. Studies in this domain are urgently
needed to minimize the impact of the outbreak. Govern-
ment agencies have quickly incorporated recent scien-
tific findings into public policies at the community,
regional, and national levels to slow down and/or pre-
vent the further spread of the COVID-19. We recom-
mend that the scholarly community conduct further
research to provide valid and reliable ways to manage
this kind of public health emergency in both the short-
term and long-term.
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